Clinical Trials Sponsored by Bond Avillion 2 Development LP

Total 6 results

Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (DENALI)

Asthma

United States, Germany, Ukraine, Serbia, Czechia, Argentina, Slovakia
Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma (TYREE)

Exercise Induced Bronchospasm

United States
Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (MANDALA)

Asthma

United States, Canada, Germany, Spain, South Africa, United Kingdom, Slovakia, Argentina, Ukraine, Serbia, Czechia
Bond Avillion 2 Development LP

Completed

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. (BLANC)

Asthma

United States
Bond Avillion 2 Development LP
Avillion LLP

Completed

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States, Germany, Bulgaria, Canada, Czechia, Hungary, Poland
Bond Avillion 2 Development LP
Parexel

Active, not recruiting

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Asthma

United States

3

Subscribe